Tectonic Therapeutic (NASDAQ:TECX) Trading 4.1% Higher

Shares of Tectonic Therapeutic (NASDAQ:TECX) traded up 4.1% during mid-day trading on Wednesday . The stock traded as high as $17.48 and last traded at $17.12. 10,933 shares were traded during trading, a decline of 54% from the average session volume of 23,742 shares. The stock had previously closed at $16.44.

Wall Street Analyst Weigh In

TECX has been the subject of a number of analyst reports. Piper Sandler initiated coverage on Tectonic Therapeutic in a report on Wednesday, June 26th. They issued an “overweight” rating and a $76.00 price target for the company. SVB Leerink started coverage on Tectonic Therapeutic in a research report on Wednesday. They set an “outperform” rating and a $49.00 price target for the company. TD Cowen initiated coverage on Tectonic Therapeutic in a research report on Monday, June 24th. They set a “buy” rating for the company. Finally, Leerink Partnrs raised Tectonic Therapeutic to a “strong-buy” rating in a research report on Wednesday.

Tectonic Therapeutic Stock Up 3.8 %

The firm has a market cap of $791.93 million, a P/E ratio of 25.57 and a beta of 2.63.

Tectonic Therapeutic (NASDAQ:TECX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Tectonic Therapeutic will post -5 earnings per share for the current fiscal year.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.